Prostate Cell News Volume 12.00 | Jan 8 2021

    0
    25







    2020-01-8 | PCN 12.00


    Prostate Cell News by STEMCELL Technologies
    Vol. 12.00 – 8 January, 2021
    TOP STORY

    Single-Cell Analysis Reveals Transcriptomic Remodelings in Distinct Cell Types that Contribute to Human Prostate Cancer Progression

    Researchers showed that activated endothelial cells were enriched in castration-resistant prostate cancer and promoted cancer cell invasion. They created a user-friendly web interface for users to explore the sequenced data.
    [Nature Cell Biology]

    Abstract

    Explore scientific events this January with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    Post-Transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer

    Scientists showed that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine (NE) transdifferentiation. In clinical prostate cancer (PC) samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with androgen receptor signaling.
    [Cell Reports]

    Full ArticleGraphical Abstract

    MAOA Promotes Prostate Cancer Cell Perineural Invasion through SEMA3C/PlexinA2/NRP1-cMET Signaling

    Investigators report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of perineural invasion (PNI) in prostate cancer (PC). MAOA promoted PNI of PC cells in vitro and tumor innervation in an orthotopic xenograft model.
    [Oncogene]

    Abstract

    WLS-Wnt Signaling Promotes Neuroendocrine Prostate Cancer

    Scientists report that the Wnt secretion mediator Wntless (WLS) is a major driver of neuroendocrine prostate cancer and aggressive tumor growth in vitro and in vivo.
    [iScience]

    Full ArticleGraphical Abstract

    Vitamin D Sufficiency Enhances Differentiation of Patient-Derived Prostate Epithelial Organoids

    To determine vitamin D regulation of prostatic epithelial differentiation, patient-derived benign prostate epithelial organoids were grown in vitamin D deficient or sufficient conditions.
    [iScience]

    Full ArticleGraphical Abstract

    Nerve Growth Factor Interacts with CHRM4 and Promotes Neuroendocrine Differentiation of Prostate Cancer and Castration Resistance

    The authors showed that an androgen-deprivation therapy-stimulated transcription factor, ZBTB46, upregulated NGF via ZBTB46 mediated-transcriptional activation of nerve growth factor.
    [Communications Biology]

    Full Article

    Identification of PIM1 Substrates Reveals a Role for NDRG1 Phosphorylation in Prostate Cancer Cellular Migration and Invasion

    Investigators performed a direct, unbiased chemical genetic screen to identify pro-viral integration site for Moloney murine leukemia virus-1 (PIM1) substrates in prostate cancer cells.
    [Communications Biology]

    Full Article

    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Loss and Revival of Androgen Receptor Signaling in Advanced Prostate Cancer

    The authors review the molecular mechanisms that enable cancer cells to switch from an androgen receptor (AR)-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.
    [Oncogene]

    Full Article

    LOX-1 and Cancer: An Indissoluble Liaison

    Scientists outline the role of LOX-1 in tumor spreading and metastasis, evidencing its function in VEGF induction, HIF-1alpha activation, and MMP-9/MMP-2 expression, pushing up the neoangiogenic and the epithelial-mesenchymal transition process in glioblastoma, osteosarcoma, prostate, colon, breast, lung, and pancreatic tumors.
    [Cancer Gene Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

    Myovant Sciences and Pfizer Inc. announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone receptor antagonist – in oncology and women’s health in the US and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the US and Canada, excluding certain Asian countries.
    [Myovant Sciences GmbH.]

    Press Release

    FEATURED EVENT

    Antibodies and Vaccines as Drugs for COVID-19

    January 13 – 14, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Somatic Origin of Cancer

    Medical University of GdaÅ„sk – GdaÅ„sk, Poland

    Scientific Communities & Communications Specialist

    STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada

    Senior Manager – FACS-Based Characterization

    Fondazione Human Technopole – Milan, Italy

    Research Associate/Assistant – Immuno-Oncology

    Scripps Research Institute – La Jolla, California, United States

    Research Fellow – Prostate and Kidney Cancers

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter